December 11, 2023 news
Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg
Onco AI-Med is an international collaborative alliance founded by Indivumed to advance personalized medicine in cancer by bringing together the combined knowledge and experience of oncologists from leading cancer clinics and research institutions around the world. Indivumed Therapeutics welcomed members of the Oncology Alliance For Individualized Medicine to its global headquarters in Hamburg, Germany for the Onco AI-Med annual board meeting.Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg Read more
December 07, 2023 news
BIO Deutschland Yearbook 2023/2024
We are pleased to again be featured in the BIO Deutschland Yearbook for 2023/2024 and proud to be a part of the rapidly growing European biotech industry, looking forward to continuing our success in 2024. Read our feature interview and profile here.BIO Deutschland Yearbook 2023/2024 Read more
November 28, 2023 news
Standardizing tissue quality: Your key to accurate early discovery insights
In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer.Standardizing tissue quality: Your key to accurate early discovery insights Read more
September 21, 2023 news
Precision therapeutics: optimizing early discovery
Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.Precision therapeutics: optimizing early discovery Read more
Join us at our poster presentation at AACR.
Come and meet us at AACR 2024 in San Diego. Stop by and join our poster presentation on April 7 from 1.30 - 5.00pm. We look forward to seeing you there!
We look forward to meeting you at DBT 2024 in Berlin.
Meet Hans Vanhooren, our VP Business Development, and Kristin Maack, VP Marketing & Corporate Communications, in Berlin and get in touch with them from April 16 - 17.
We look forward to meeting you at BIO-Europe Spring in Barcelona in March.
Meet our VP Business Development Hans Vanhooren and Joana Utrera, Director Country Operations Iberia, on site and get in touch with them in Barcelona from March 18 - 20.
January 16, 2024 publication
Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024)Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024) Read more
October 21, 2023 poster
Poster Bischof et al. 2023 Combining cancer patient spatial transcriptomics and bulk rna-seq data to drive insights into NSCLCPoster Bischof et al. 2023 Combining cancer patient spatial transcriptomics and bulk rna-seq data to drive insights into NSCLC Read more
October 09, 2023 publication
Yuyi, H. et al. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient Cell Death Discovery 9, 370 (2023)Yuyi, H. et al. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient Cell Death Discovery 9, 370 (2023) Read more
October 02, 2023 publication